STOCK TITAN

Mannkind reported $349.0M in revenue and $5.9M in net income for fiscal 2025. See the full MNKD financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

MannKind to Present at Upcoming Investor Conferences

MannKind (MNKD) will participate in two upcoming investor conferences in New York in September 2026.

(Neutral)
(Neutral)
Tags
conferences

MannKind (MNKD) will participate in two upcoming investor conferences in New York in September 2026. Management will join a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 11:30 a.m. ET, and at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 9:30 a.m. ET. Live audio webcasts and 90-day replays will be available on MannKind’s investor relations website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences:

Cantor Global Healthcare Conference (New York, NY)
Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Links to the live audio webcasts of the presentations will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.



Contacts:
Investor Relations
Kate Miranda
ir@mnkd.com

Media Relations
Christie Iacangelo
media@mnkd.com

FAQ

When will MannKind (MNKD) present at the Cantor Global Healthcare Conference?

MannKind will participate in a fireside chat at the Cantor Global Healthcare Conference in New York on Thursday, September 10, 2026, at 11:30 a.m. ET. The session will be accessible via a live audio webcast on the company’s investor relations website.

What is the date and time of MannKind (MNKD)’s presentation at the H.C. Wainwright 28th Annual Global Investment Conference?

MannKind is scheduled for a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Tuesday, September 15, 2026, at 9:30 a.m. ET. Investors can listen through a live audio webcast available on the company’s website.

How can investors access the live webcasts of MannKind (MNKD)’s September 2026 conference presentations?

Live audio webcasts of MannKind’s fireside chats at both September 2026 conferences will be available at https://investors.mannkindcorp.com/events-and-presentations on the company’s investor relations website.

Will replays of MannKind (MNKD)’s September 2026 conference presentations be available?

Yes. A recorded version of each MannKind investor conference presentation will be available on the company’s investor relations website for approximately 90 days following the conference.